Iza-bren

Phase 3Small molecule

Bristol-Myers Squibb

Iza-bren is one of 76 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerActive, not recruiting

Non-Small Cell Lung CancerNot yet recruiting

Urothelial CancerRecruiting

Triple-Negative Breast CancerPhase 2/Phase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Not yet recruiting

Urothelial CancerPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Iza-bren

Bristol-Myers Squibb

Phase 3

2 3

Lenvima

Eisai

Preclinical

6 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Treatment

GSK

Preclinical

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Not yet recruiting

Phase 1

NCT07382726

Q2 2030

Phase 2/3Recruiting

Triple-Negative Breast Cancer

NCT06926868

Q4 2030

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT07100080

Q4 2031

Phase 3Not yet recruiting

Non-Small Cell Lung Cancer

NCT07680790

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT07680790·850 enrolled

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07100080·500 enrolled

Triple-Negative Breast Cancer1 trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT06926868·500 enrolled

Phase 11 trial

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07382726·18 enrolled

Urothelial Cancer1 trial

IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Preclinical·NCT07106762·470 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Iza-bren. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iza-bren compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iza-bren. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Iza-bren

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q2 2030

Q4 2030

Q4 2031

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Triple-Negative Breast Cancer1 trial

Phase 11 trial

Urothelial Cancer1 trial

References

Drug Info

Quick Facts

Related News